GeneDx completed a significant acquisition of Fabric Genomics on May 5, 2025, driving dramatic growth across all financial metrics including 40% revenue increase and transformation from negative to positive operating cash flow.
The acquisition of Fabric Genomics represents a transformative event that has substantially expanded GeneDx's capabilities in AI-powered genomics and significantly scaled the business. The company's strategic pivot is evident in updated mission language that shifts from broad "personalized medical care" to more focused "healthiest life through genomics," suggesting refined market positioning.
The acquisition drove exceptional growth with revenue jumping 40% to $427.5M and the company achieving a remarkable turnaround in operating cash flow from -$28.5M to +$33.3M. While net losses improved significantly by 60% to -$21.0M and gross profit grew 53%, the integration required substantial investment with R&D expenses increasing 58% and capital expenditures surging 246%. The doubling of both current liabilities and accounts receivable, along with the 35% increase in current assets, reflects the substantial scale expansion from the merger, positioning the company for accelerated growth despite near-term integration costs.
Capital expenditure jumped 246.3% — major investment cycle underway; assess returns on deployment.
Operating cash flow surged 216.8% — exceptional cash generation, highest quality earnings signal.
Current liabilities surged 98.7% — significant near-term obligations; verify ability to meet short-term debt.
Receivables surged 97.6% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.
Net income grew 59.8% — bottom-line growth signals improving overall business health.
R&D investment increased 57.5% — signals commitment to future product development, though near-term margin impact.
Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Strong top-line growth of 40% — accelerating demand or successful expansion into new markets.
Current assets grew 35.5% — improving short-term liquidity or inventory/receivables build.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →